Research To Practice | Oncology Videos
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
Episodes
Ovarian Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00) CME information and select publications
Ovarian Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00) CME infor
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics: Introduction (0:00) New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20) Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33) Potential Role of
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 4 with Dr Sara M Tolaney
Featuring perspectives from Dr Sara M Tolaney, including the following topics: Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00) Managing brain metastases in triple-negative breast cancer (6:30) EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11) PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 3 with Dr Sara M Tolaney
Featuring perspectives from Dr Sara M Tolaney, including the following topics: Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00) First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13) First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02) Antibody-drug conjugates for pr
Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics: Introduction (0:00) Minimal Residual Disease Assays in Community-Based Practice (1:24) New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12) Richter Transformation (30:43) Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (
HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00) Case: A woman in her mid 50s with ovari
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics: Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00) Management of BsAb-induced cytokine release syndrome and other toxicities (7:35) Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningS
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr L Elizabeth Budde, including the following topics: Overview of approved and investigational CD20 x CD3 bispecific antibodies (BsAbs) in non-Hodgkin lymphoma; key findings from Phase II studies evaluating glofitamab and epcoritamab in relapsed/refractory (R/R) diffuse large B-cell lymphoma (0:00) Bringing BsAbs into earlier-line s
Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) EGFR Mutations (2:23) HER2 Alterations (22:40) Available and Investigational Immunotherapies (32:14) Small Cell Lung Cancer (40:48) CME information and select publications
Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal
Featuring an interview with Dr Neeraj Agarwal, including the following topics: Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00) Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13) Potential usage of capivasertib as second-line therapy for metastatic androgen pathway
Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Neeraj Agarwal, including the following topics: Therapeutic targets of systemic therapy in prostate cancer (0:00) Prevalence of genomic alterations in prostate cancer including PTEN deficiency; prognostic and predictive value (3:52) Optimal timing of and approach to PTEN assessment; pathophysiology surrounding PTEN loss (9:29
Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications
HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00) Commentary: Role of HER2-dire
Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications
For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon
Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 5
Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo
Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian
Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics: Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00) Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09) Key findings from the Phase III ROSELLA study (7:
Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48) Management of HER2-Positive Gastroesophageal Cancer (25:11) Neoadjuvant Therapy for Gastroesophageal Cancer (45:13) Note to listeners: Subsequent to the recording of this sympos
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Therapy (2:48) Relapsed/Refractory Disease (39:30) CME information and select publications
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics: Introduction (0:00) Trials in Progress (1:12) Chronic Lymphocytic Leukemia (7:09) Diffuse Large B-Cell Lymphoma (32:35) Mantle Cell Lymphoma (58:25) Follicular Lymphoma (1:14:49) CME information and select publications
HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic: Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann CME information and select publica
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics: Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00) Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20) DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strateg
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon
Featuring perspectives from Dr David W Cescon, including the following topics: Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00) CNS activity of TROP2-directed antibody-drug conjugates (5:36) Autoimmune considerations with immunotherapy (10:09) Treatment of oligoprogressive advanced breast cancer (17:31) CME information and select publications
Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon
Featuring perspectives from Dr David W Cescon, including the following topics: First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00) First-line treatment of mTNBC in patients eligible for immunotherapy (12:05) Adverse events (19:39) CME information and select publications
Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics: Introduction (0:00) Preventing Ovarian Cancer (1:04) Endometrial Cancer (5:27) Ovarian Cancer (25:36) Cervical Cancer (54:04) CME information and select publications
Metastatic Bladder Cancer — Rapid Case Review Issue 8
Featuring perspectives from Dr Alexandra Drakaki, including the following topics: Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00) Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic
Metastatic Bladder Cancer — Rapid Case Review Issue 7
Featuring perspectives from Dr Alexandra Drakaki, including the following topics: Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00) Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointe
Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18) HER2-Positive Breast Cancer — Dr Bardia (42:46) Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41) CME information and select publications
Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (1
Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of t
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TK
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture)
Featuring a slide presentation and related discussion from Prof Andreas Hochhaus, including the following topics: · Historical evolution of the treatment landscape for chronic myeloid leukemia and goals of clinical care (0:00) · Current therapeutic landscape and available long-term data (10:22) · Mechanism of action of asciminib and key findings from the ASC4FIRST study (16:50)
Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer
Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and h
Non-Small Cell Lung Cancer — Targeting KRAS G12C
Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics: Introduction (0:00) Best Option for Your Patient (1:28) Biological Considerations (6:26) KRAS G12C Inhibitors (11:33) Second-Line Treatment (13:02) Current Clinical Trials in the First-Line Metastatic Setting (32:18) Current Clinical Trials in the Localized Setting (49:52) Current Clinical Tria
Prostate Cancer — The Optimal Use of Hormonal Therapy
Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics: Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00) Nonmetastatic Disease (10:32) Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50) CME information and select publications
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00) Case: A man in h
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof John Seymour, including the following topics: Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00) Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21) First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10) CME information and select publications
AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metast
ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists
Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics: Introduction (0:00) HER2 History (1:32) Cases from the GMO Survey (7:06) Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56) Faculty Case Presentations (31:37) Patterns of Care Survey — Part 1 (38:26) Optimizing the Use of Up-F
Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program
Featuring perspectives from Dr William G Wierda, including the following topics: Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00) Sequencing Road Map (12:39) Key Datasets — Pirtobrutinib (21:08) Investigator Survey (34:09) Chimeric Antigen Receptor T-Cell Therapy (45:08) Other Novel Therapy Approaches (49:58) EHA 2026 (54:45) CME information and select pu
Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal (Companion Faculty Lecture)
Description: Featuring a slide presentation and related discussion from Prof Ticiana Leal, including the following topics: · Incidence, pathophysiology and clinical presentation (0:00) · Diagnostic challenges and evaluation process (3:37) · Treatment modalities and therapeutic options (10:01) · Mechanistic effects and key clinical trial data for amifampridine (12:20) ·
Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal
Featuring an interview with Prof Ticiana Leal, including the following topics: Pathophysiology and clinical signs and symptoms (0:00) Screening and/or diagnostic approaches (5:45) Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36) Key clinical trial data for amifampridine and practicalities of its administration (14:05) Building awareness
For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics: Introduction (0:00) Overview of Prostate Cancer (3:00) Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12) Potential Role of Capivasertib in Metastatic HSPC (27:22) Current and Potential Future Role
Metastatic Triple-Negative Breast Cancer — Patterns of Care
Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics: Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00) First-Line Therapy (PD-L1 Negative) (6:53) First-Line Therapy (PD-L1 Positive) (23:40) Second-Line Therapy (Sequencing) (34:08) Adverse Events with TROP2-Targeting ADCs (43:43) CME inf
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00) Case: A ma
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pe
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics: Introduction: Lymphoma Survivorship (0:00) Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49) Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14) CME information and select publications
Non-Hodgkin Lymphoma | Sonali M Smith, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Novel Treatment Approaches for Non-Hodgkin Lymphoma | Faculty Presentation 2: Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Sonali M Smith, MD CME information and select publications
Non-Hodgkin Lymphoma | Matthew Matasar, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Novel Treatment Approaches for Non-Hodgkin Lymphoma | Faculty Presentation 1: Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Matthew Matasar, MD CME information and select publications
HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway
Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics: Introduction: San Antonio Memories (0:00) PI3K/AKT/PTEN Alterations and Therapies (7:18) Capivasertib (20:22) Gedatolisib (34:08) Inavolisib (47:07) New Agents and Ongoing Trials (52:34) CME information and select publications
For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics: · Introduction (0:00) · Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29) · Recent Advances in Up-Front Treatment for Metastatic PAD (15:47) · Selection and Sequencing of Ther
Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Hope S Rugo, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 2: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Hope S Rugo, MD CME information and select publications
Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Virginia Kaklamani, MD, DSc
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 1: Identification of Appropriate Candidates with HR-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway; Role in the Up-Front Setting — Virginia Kaklamani, MD, DSc C
AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generatio
AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics: Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00) Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that p
Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics: Introduction (0:00) Biomarker Evaluation in Localized and Metastatic Disease (1:49) Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37) Other Available Therapeutic Approaches — Dr Shitara (33:22) CME information and select publications
Gastroesophageal Cancers | David H Ilson, MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gastroesophageal Cancers | Faculty Presentation 1: Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — David H Ilson, MD, PhD CME information and select publications
Gastroesophageal Cancers | Kohei Shitara, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gastroesophageal Cancers | Faculty Presentation 2: Other Available Therapeutic Approaches — Kohei Shitara, MD CME information and select publications
Genitourinary Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics: Introduction: Welcome GU Oncology Fellows! (0:00) Prostate Cancer — Dr Aggarwal (12:48) Urothelial Bladder Cancer — Dr Galsky (45:01) Renal Cell Carcinoma — Dr Zhang (1:10:52) CME information and select publications
For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: · Introduction (0:00) · Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) · Practical Considerations with Oral SERDs (15:42) · Pot
Metastatic Bladder Cancer — Rapid Case Review Issue 6
Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00) Case: A man in his early 70s with diabetes who received adjuvant
Metastatic Bladder Cancer — Rapid Case Review Issue 5
Featuring perspectives from Prof Yohann Loriot, including the following topics: Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00) Case: A man in his early 90s with
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics: Introduction (00:00) Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47) Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15) ASCO and EH
Multiple Myeloma | Robert Z Orlowski, MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma — Robert Z Orlowski, MD, PhD CME information and select publications
Multiple Myeloma | Amrita Krishnan, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T‑Cell Therapy, Bispecific Antibodies and Antibody‑Drug Conjugates — Amrita Krishnan, MD CME information and select publications
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatm
Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium
Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics: Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00) Case: A man in his la
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16) Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21) CAR T-Cell Therapy for Other Ly
Prostate Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Curr
Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Associati
For Oncology Nurses: Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) C
Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential
Gastroesophageal Cancers — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics: Introduction (0:00) HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08) Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54) Available Immunotherapeutic Strategies for Advanced Gastroesophag
Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Tim
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR
Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics: Introduction: Relative Impact of Targeted Treatment (0:00) HER2 Alterations (8:04) KRAS Mutations (24:25) MET Overexpression (30:34) ALK Fusions (32:34) ROS1 Fusions (42:36) RET Fusions (52:00) CME information and select publications
Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Maurice Pérol, MD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting ALK, ROS1 and RET — Maurice Pérol, MD CME information and select publications
Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | John V Heymach, MD, PhD
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting HER2, MET and KRAS G12C — John V Heymach, MD, PhD CME information and select publications
For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Po
Recommended
紐約鳥｜New York Aperture
The Swerve Podcast: Obscure Topics | Conspiracy Theories
The Bread and Banter Podcast
The Church of What's Happening Now: The New Testament
Busted Open
Deadline: White House
Crickets Corner
History of the Earthquake and Fire in San Francisco
Fox news
K-Drama Obsessed Mamas | Beyond “Just One More Episode!”
True Crime Classics
The Healer Revolution
